🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesTirzepatide cardiovascular safety — need advice Page 3

Tirzepatide cardiovascular safety — need advice

Dr.RaviCardio Thu, Mar 7, 2024 at 2:00 PM 14 replies 2,252 viewsPage 3 of 3
FranDenver
Member
267
1,123
Oct 2024
Denver, CO
Mar 10, 2024 at 8:22 AM#11
sophie_paris said:
SURMOUNT-1 landed around 20.9% mean weight loss at 15mg over 72 weeks, against roughly 15% for semaglutide 2.4mg in STEP 1.

Bookmarking. The distinction being drawn above is the one nobody else makes. Sending this to two other people who asked me the same thing last week.

2 0Dr.RenalNash, LipidDoc_ATL
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Mar 12, 2024 at 6:46 PM#12

Clinical perspective, offered as context rather than as advice.

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

Last edited: Mar 12, 2024 at 7:46 PM
3 1KarenAZ_mom, zoe_NC, Dr.ObesityLA
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Mar 15, 2024 at 5:09 AM#13
Dr.LeslieOBGYN said:
The GIP arm is doing real work rather than padding the label.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.

4 2MarkLI_maint, Dr.PeteFamMed, claudia_zurich and 1 other
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Mar 17, 2024 at 3:31 PM#14
Dr.RaviCardio said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -2.1 lbs/week average
Fasting glucose (finger stick): stable at 84 mg/dL
Blood pressure (home): 116/74 average
Resting heart rate: 64 bpm (down from 80)
Waist circumference: down 14 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

5 3amsterdam_pete, LondonLisa, mike_nyc and 2 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Mar 20, 2024 at 1:51 AM#15

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Thread quality here is what the rules are for. Keep it up.

Last edited: Mar 20, 2024 at 3:51 AM
6 4PurityPaulOR, MaxMetOK, MounjBrad and 3 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register